Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Short-term Investments (2022 - 2025)

Indivior Pharmaceuticals has reported Short-term Investments over the past 4 years, most recently at $1.0 million for Q1 2025.

  • For Q1 2025, Short-term Investments rose 125.0% year-over-year to $1.0 million; the TTM value through Mar 2025 reached $1.0 million, up 125.0%, while the annual FY2024 figure was -$17.0 million, 62.22% up from the prior year.
  • Short-term Investments for Q1 2025 was $1.0 million at Indivior Pharmaceuticals, roughly flat from $1.0 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $415.0 million in Q4 2023 and troughed at -$233.0 million in Q3 2022.
  • A 4-year average of $16.0 million and a median of -$1.5 million in 2024 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: surged 248.74% in 2023 and later plummeted 99.76% in 2024.
  • Year by year, Short-term Investments stood at $119.0 million in 2022, then surged by 248.74% to $415.0 million in 2023, then plummeted by 99.76% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Business Quant data shows Short-term Investments for INDV at $1.0 million in Q1 2025, $1.0 million in Q4 2024, and $30.0 million in Q3 2024.